Hospital General Gregorio Maranon

Madrid 28009

0 studies enrolling now · 5 studies all time

What they study most

Antimetabolites, Antineoplastic, Breast Cancer, Breast Neoplasms, Breast Tumor, Cancer of the Breast, Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, Endocrine System Diseases, Estrogen Receptor- Negative Breast Cancer, Gemcitabine, HER2- Negative Breast Cancer

Studies at this site

• Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes — Completed
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) — Completed
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — Completed
• Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant — Stopped early
• Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis — Completed